Filing Flows › Comparisons › HRTX vs BCYC
Heron Therapeutics vs Bicycle Therapeutics: HRTX and BCYC compared
Heron Therapeutics is the larger company: $35.2M of revenue in its latest quarter (Q3 2026) against $34.1M for Bicycle Therapeutics (Q3 2026). Bicycle Therapeutics is growing faster (+190% against -8% a year earlier). Heron Therapeutics is more profitable, with an operating margin of -4.7% against -39.6%.
Where the money goes: HRTX and BCYC
Heron Therapeutics (HRTX) · Q3 2026
Heron Therapeutics, Q3 2026: revenue $35.2M (-8% year over year), operating margin -4.7%, net loss $5.0M, operating cash flow −$794K. The chart follows the revenue to costs, profit and cash.
Bicycle Therapeutics (BCYC) · Q3 2026
Bicycle Therapeutics, Q3 2026: revenue $34.1M (+190% year over year), operating margin -39.6%, net loss $10.5M, operating cash flow −$40.3M. The chart follows the revenue to costs, profit and cash.
| Heron Therapeutics (HRTX) | Bicycle Therapeutics (BCYC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $35.2M | $34.1M |
| Revenue growth, Y/Y | -8% | +190% |
| Operating margin | -4.7% | -39.6% |
| Net earnings | −$5.0M | −$10.5M |
| Net margin | -14.2% | -30.8% |
| Operating cash flow | −$794K | −$40.3M |
Where the revenue comes from
Heron Therapeutics
- CINVANTI: $20.0M (57%)
- ZYNRELEF: $10.6M (30%)
- Aponvie: $4.5M (13%)
- SUSTOL: $152K (0%)
Questions
Which is bigger, Heron Therapeutics or Bicycle Therapeutics?
Heron Therapeutics is the larger company: $35.2M of revenue in its latest quarter (Q3 2026) against $34.1M for Bicycle Therapeutics (Q3 2026).
Is Heron Therapeutics or Bicycle Therapeutics growing faster?
Bicycle Therapeutics is growing faster (+190% against -8% a year earlier).
Which is more profitable, Heron Therapeutics or Bicycle Therapeutics?
Heron Therapeutics is more profitable, with an operating margin of -4.7% against -39.6%.
More: Heron Therapeutics earnings · how Heron Therapeutics makes money · Bicycle Therapeutics earnings · how Bicycle Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.